sarepta therapeutics fda - Search News

Order byBest matchMost fresh

News

FDA, Sarepta

Sarepta Stock Falls. Why It’s Caving Into the FDA and What Comes Next.

The company agreed to voluntarily halt shipments of its experimental medicine Elevidys for Duchenne muscular dystrophy.

Continue reading

· 1d · on MSN

Sarepta stock extends decline as company declines FDA call to withdraw drug

· 23h · on MSN

Sarepta extends losses premarket after refusing FDA’s halt request

FDA Shuts Down Sarepta Gene Therapy Trials

Fierce Pharma · 19h

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market

As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm behind its approved Duchenne muscular dystrophy (DMD) treatment. | As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head,

Continue reading

· 3d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

· 4h · on MSN

Sarepta to pause Elevidys gene therapy shipments in U.S.

In surprise reversal, Sarepta Therapeutics says it will pause shipments of Duchenne gene therapy

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

21h

Sarepta Therapeutics: Why Is SRPT Stock Crashing?

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results